Tang Capital Management ABEO Position
ActiveTang Capital Management initiated a new position in ABEONA THERAPEUTICS INC. (ABEO) in Q4 2025, holding $5.3M worth of shares across 1,000,000 shares.
1 other tracked fund also holds ABEO.
Short interest stands at 28.1% of float with 15.2 days to cover, indicating significant bearish positioning against Tang Capital's long thesis.
About ABEONA THERAPEUTICS INC.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Full company profile →Short Interest
28.1%
15.2 days to cover
Frequently Asked Questions
Does Tang Capital Management own ABEO?
Yes. As of Q4 2025, Tang Capital Management holds 1,000,000 shares of ABEONA THERAPEUTICS INC. (ABEO) valued at $5.3M. This data comes from their SEC 13F filing.
How many hedge funds own ABEO?
2 specialist biotech hedge funds currently hold ABEO, including Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy ABEO?
Tang Capital Management's position in ABEO was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's ABEO position increasing or decreasing?
Tang Capital Management initiated a new position in ABEO in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ABEOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →